

# Index

- A**
- AAF/II fimbriae, 336
  - AAF/II fimbrial projection, 37
  - AAF-fibronectin, 332
  - AAF-fibronectin-integrin binding mechanism, 336
  - ACE527 vaccine, 252
  - Adherent invasive *E. coli* (AIEC), 330, 344
    - adhesion, 285–287
    - in CD, 285
    - diversity, 288–289
    - E. coli* strains, 285, 294
    - in IBD, 285
    - intracellular survival, 287–288
    - invasion, 287
  - Adhesins, 207, 328
    - Afa/Dr, 331
      - bacterial, 333, 335
      - fimbrial, 325, 329, 334, 335
      - FimH tip, 329, 330
      - microbial, 328
      - nonfimbrial, 329, 334, 335
  - Adhesion
    - AA pattern, 40
    - diffuse adhesion (DA), 28
    - EAEC 042, 31, 47
    - HEp-2 cells serogroups, 46
    - human leukocyte adhesion proteins, 39
    - ICAM-1, 42
  - Afa/Dr adhesins, 331
    - Afa/Dr DAEC invasion capacity, 132
    - general characteristics, 129
    - hCEACAM, 130
    - human decay-accelerating factor, 129–130
  - AfaE/DraE/DaaE subunits, 128
  - Affinity biomolecular interactions, high, 335
  - aggR* genes, 105
  - Aggregative adherence (AA), 346
  - Aggregative adherence fimbriae (AAF), 46, 331
  - Aggregative virulence plasmids, 33
  - Air sac disease, 210, 211
  - Alberta Provincial Pediatric Enteric Infection TEam (APPETITE), 362
  - Allele-specific oligonucleotides (ASOs), 352
  - Alpha-hemolysin (HlyA), 207
  - Alternative laboratory diagnostic methods, 357
  - America, *Escherichia coli* Diagnosis in, 360–363
  - American clinical laboratories, 360
  - Amino acid residues, 326
  - Aminoglycosides, 305
  - Ampicillin-resistant *E. coli*, 310, 311, 313
  - Amplicon, 352
  - Amplicon detection technology, 348
  - Amplification strategy technology, 348
  - Amplified target sequences, 352
  - Anaerobic atmosphere, 324
  - Ancestral phylogenetic clonal group B2, 308
  - Andrade, G.I., 155
  - Animal assays, 357
  - Anionic polysaccharides, 329
  - Antibiotic treatment of animals, 305
  - Antibiotic resistance gene transmission, 315
  - Antibiotic resistance in *E. coli*, 302–307, 309–316
    - antibiotic resistance and pathogenesis, 309
    - clinical studies, 306, 307
    - concepts about mechanisms of, 302–305
      - antibiotic use in animals and, 304–305
      - $\beta$ -lactam resistance, 303–304

- Antibiotic resistance in *E. coli* (*cont.*)  
 mechanisms of, 302–303  
 quinolone resistance, 304  
 phylogenetic and epidemiology, 307–309  
 strains, 313  
 studies in the Americas, 309–316  
   implications for management and  
   stewardship programs, 315–316  
   in North and Central America, 309–312  
   South America, 312–315
- Antibiotic-resistant organisms in pediatric, 310
- Antibiotics feeding to farm animals, 304
- Anti-CK8, 336
- Antigen synthesis strategy, 357
- Anti-inflammatory molecule, 328
- Anti-LPS antibodies, 357
- Antimicrobial Resistance and Infection  
 Prevention and Control, 312
- Antimicrobial resistance mechanisms, 302, 303
- Antimicrobial stewardship programs, 316
- Antimicrobial susceptibility, surveillance  
 study of, 312
- Anti-Poly-N-acetyl glucosamine, 266
- Anti-STa immunogenicity, 257
- Argentina, 113, 115–117
- Asialo-glycosphingolipids, 329
- ATP-binding cassette (ABC), 302
- Attaching-effacing (A/E) lesions, 290, 345
- Atypical EPEC (aEPEC), 336, 344  
 ability of, 81  
 adult volunteers, tEPEC, 86  
 AE lesion, 79  
 196 aEPEC strains, 83  
 in America, 86–91  
 animals, food and environment, 90  
 anti-FlhD serum, 85  
 AT proteins, 83  
 cycle inhibiting factor (Cif), 82  
 diarrhea hampers, 86  
 diarrheagenic *E. coli*, 77  
 enteropathogens, 77  
 EspT virulence mechanism, 82  
 flagellin (FlhC), 85  
 HeLa/HEp-2 cells, 78  
 intimin-dependent pathway, 80  
 94 kDa-outer-membrane protein, 80  
 LEE-virulence genes, 79  
 neural Wiskott-Aldrich syndrome protein, 80  
 Nle-encoding genes, 82  
 non-LEE effectors (Nle), 81  
 PAI, 79  
 PAI-O122, 82  
 PerA protein, 79  
 phenotypic characteristics, 78  
 serotypes O8:HNM and O119:H6, 79  
 subclassification, 78  
 T3SS-dependent mechanism, 85  
 T3SS-dependent non-LEE effectors  
   genes, 82  
 and tEPEC, 78  
 tir–intimin interaction, 80
- Autophagy-related 16-like-1 (ATG16L1), 288
- Autotransporter (AT) proteins, 37, 83
- Avian pathogenic *E. coli* (APEC), 160–161,  
 208–212, 214, 215, 242
- B**
- Bacteremia, 206, 207, 211, 213, 214
- Bacteria  
 commensal intestinal, 328  
 pH-resistant, 324
- Bacteria–host interaction, 324–326
- Bacterial adhesins, 333, 335
- Bacterial efflux pumps, 302
- Bacterial genomics research, 352
- Bacterial glycans, 330
- Bacterial glyco-engineering technology, 357
- Bacterial pathogens, 325, 327, 330, 335
- Bacterial protein secretion. *See* Protein  
 secretion systems
- Bacteriological methods, 361
- Barletta, F., 88
- Basal membrane, EM of, 325
- Baudry, 33
- BD Max enteric bacterial panel (BD  
 Diagnostics), 350
- BD Max system, 350
- Bentancor, A., 153, 158
- Bicalho, M., 162
- Bicalho, R., 162
- Biochemical method, 355
- Biochemical tests, 347
- Biochemically complex gel, 326
- Biofilm, 182–183  
 bacteria-mucus biofilm, 38  
 formation of, 327  
 mucoid biofilm formation, 34
- Bioinformatics analysis, 353
- Biological Hazards (BIOHAZ) panel, 105
- Biotinylated type (TBP) primer, 352
- Biotyper (BrukerDaltonics), 355
- Bladder epithelial cells, 329
- Blanco Crivelli, X., 154, 159
- Bloodstream infection, clinical evaluation of, 306
- Bloody diarrhea (BD) patients, 359
- Bolivia, 115
- Bovine mucus, 329

Brazil, 114, 211, 215  
 Briñez, W.J., 184  
 Broad spectrum penicillins, 303  
 Broiler chickens with *E. coli* septicemia, 307  
 Bronchitis virus, 211  
 Brusa, V., 179  
 Bundle-forming pilus (BFP), 60, 62, 329, 334

## C

Callaway, T., 164  
 Canada, 110–112  
 Carbapenem-resistant *Enterobacteriaceae*, 310  
 Carbapenem-resistant strain, 306  
 Carbapenems, 302  
 Carbonari, C.C., 50  
 Carcinoembryonic antigen-related cell  
   adhesion molecules (CEACAMs),  
   325, 330–331  
 Carvalho, V.M., 161  
 Cassin, M.H., 196  
 CEACAM6 expression, 331  
 CEACAM6 receptor, 285  
 Cell adhesion, 326  
 Cell–cell communication, 333  
 Cell cytoskeleton, 336  
 Cellular caveolae, 333  
 Cellular physiology, 330  
 Cellulitis, 210  
 Center for Genomic Epidemiology (CGE),  
   353  
 Centers for Disease Control and Prevention  
   (CDC), 360, 362  
 Central nervous system complications, 336  
 Centro Nacional de Referencia de  
   Bacteriología (CNRB), 115  
 Cephalosporin resistance, 316  
 Cephalosporins, 302, 304, 307  
 Cephalosporins-resistant organisms, 310  
 CGE SerotypeFinder, 353  
 Chandran, A., 153  
 Chicken, 208–211, 215  
 Chile, 114, 116  
 Cholesterol, 325, 330  
 Chondroitin/dermatan sulfate, 329  
 Chromatographic retention time, 356  
 Chromosomal genes, 302, 304, 328  
 Chromosomal  $\beta$ -lactamase genes, 307  
 Ciprofloxacin resistance, 310, 313  
*Citrobacter rodentium*, 326  
*ck8* small interfering RNA (siRNA), 336  
 Colello, R., 157  
 Coli surface antigens, 5  
 Colibacillosis, 209, 211

Coliforms, 210, 211  
 Colisepticemia, 211  
 Collagen IV, 331  
 Colon glycans, 327  
 Colonization factor antigens (CFAs), 5  
 Colonization factors (CFs), 1, 6–9, 11, 13, 14,  
   16, 19, 20, 334, 345  
 Colonization niche, 324  
 Colorectal cancer (CRC), 136  
 Commensal *E. coli*, 324, 328, 347  
 Commensal microbiota, 327  
 Conjugative plasmids, 304  
 Contiguous barrier, 326  
 Core-encoded fimbriae, 334  
 Costa Rica, 115  
 Coura, F.M., 157  
 Crohn's disease (CD), 285, 330  
 Croxen, M.A., 154  
 Cruz Junior, E.C., 155  
 CTX-M-15, 308, 309  
 CTX-M-15 gene-encoding ESBL, 307  
 CTX-M-producing *E. coli*, 314  
 CTX-M-type  $\beta$ -lactamases, 307  
 Curli fimbriae, 334  
 Cyclic adenosine monophosphate (cAMP), 4  
 Cyclic guanosine monophosphate (cGMP), 4  
 Cytokeratin-8 (CK8), 336  
 Cytokeratins, 336  
 Cytolethal distending toxin (CDT), 67, 163  
 Cytolysin A (ClyA), 5  
 Cytotoxic effect, 336  
 Cytotoxic necrotizing factor 1 (CNF1), 208

## D

DAEC, 331  
 Decay-accelerating activity, 130  
 Desilets, M., 295  
 Diagnosis, 344–347, 349, 351, 353, 357, 359,  
   360, 362  
 Diarrhea, 77  
   acute diarrhea in children, 126  
   adults, 134  
   childhood diarrheal diseases, 139  
   children, 134  
   DAEC, 125  
   DAEC-diarrhea episodes, 138  
   Dr and F1845 fimbrial adhesins, 127  
   travelers' diarrhea, 139  
 Diarrhea, Costa Rican children with, 311  
 Diarrheagenic *Escherichia coli* (DEC), 2, 314,  
   315, 327, 328, 334, 344, 348, 360  
   biofilm formation, 182–183  
   characterization and detection of, 360

- Diarrheagenic *Escherichia coli* (DEC) (*cont.*)  
 detection, 347  
 detection assays, 356  
 diarrhea caused by, 360  
 epidemiology, 360  
 in food, 178–179, 191–193  
 food microbial ecology, 180–183  
 food processing factors, 180–182  
 pathogroups, 150  
   antibacterial therapy, 267  
   azithromycin, 267  
   rehydration, 266  
   rifaximin and rifamycin, 267  
   travelers' diarrhea, 267  
 pathotypes, 360  
 strains, 315, 335
- Diarrheal disease surveillance, 352  
 Diarrheal disease, outbreaks of, 334  
 Diarrheal infection, 345, 353, 361  
 Diffuse adherent *E. coli* (DAEC), 2, 129–130,  
 132–134, 152, 314, 330, 344  
 adhesion to epithelial cells, 126  
 adults, 139–140  
 Afa/Dr adhesins (*see* Afa/Dr adhesins)  
 Afa/Dr family, 127  
 age-related diarrheal illness, 137–138  
 in the Americas, 137  
 antibiotics resistance, 140–141  
 characterization, 126  
 children, 138–139  
 definition, 126  
 detection, 135–136  
 Dr and Afa-III adhesins, 128  
 epidemiology, 137–141  
 hCEACAMs, 125, 127  
 hDAF, 125, 127  
 HIV, 140  
 infection, 131  
 prevalence, 138  
 research, 136–137  
 in travelers' diarrhea patients, 125  
 virulence factors (*see* Virulence factors)  
 virulence factors and pathogenesis, 127–129
- $\alpha$ -D-mannosylated proteins, 329  
 DNA-based assays, 344, 361  
 Dogan, B., 160  
 $\beta$ -domain, 38  
 Duopath Verotoxins Gold Labeled  
   Immunosorbent Assay, 347
- E**  
*E. coli* common pilus (ECP), 68, 334  
*E. coli* laminin-binding fimbriae (ELF), 334  
*E. coli* Nissle 1917, 291–293  
*E. coli* non-O157, 177  
*E. coli* O157, 103, 109, 110, 112  
*E. coli* ST131, 306, 308  
   colonization of camels, 307  
   global phylogeny of, 308  
   H30 subclone, 305  
 EAEC heat-stable toxin (EAST-1), 4  
 EAF probe, 69  
 Ebel, E., 196  
 EcN metabolism, 292  
 Ecology  
   DEC, 174, 180–183  
   food microbial, 181  
 EcpD tip adhesin, 6  
 Effector proteins  
   EPEC and EHEC encode, 229  
   T3SS, 223, 226  
 Efflux pumps, bacterial, 302  
 EHEC O157, 325  
 EHEC/STEC vaccines, 263–264  
   animals, 262–265  
   humans, 265  
   Stx for humans, 265–266  
 EHEC-tainted agricultural products, 334  
 EibA-C-D-E-F-G, 237  
 Electrospray ionization mass spectrometry  
   (ESI-MS), 356  
 ELISA assays, 345  
 EM proteins, 325  
 Emergency Room of a Public Hospital, 313  
 Emergent clones, 110  
 End-point multiplex PCR, 349  
 End-time PCR, 348  
 Enteroinvasive *E. coli* (EIEC)  
   diagnosis, 345  
   invasive capacity, 345  
 Enteric infections, 348  
 Enteric pathogen, 326–328, 361  
 Enteroaggregative escherichia coli (EAEC), 2,  
 105, 107–109, 151–152, 324, 327,  
 328, 344  
   AA pattern, 28  
   adherence, 34–35  
   adhesion to human intestinal mucosa, 331  
   adhesins, 47–50  
   in American countries, 48–49  
   animal models, 43–44  
   attaches to epithelial cells, 336  
   clinical features, 30  
   definition, 28–29  
   in developing countries, 42–43  
   diagnostic, 40–41  
   epidemiology, 29–30, 47

- food-borne emerging enteropathogen, 27
- histopathology, 31
- hybrid EAEC/STEC strain, 50–51
- hybrid O104:H4 STEC/EAEC Strain, 44–46
- inflammation, 36
- intestinal inflammation, 42
- mediate diarrhea, 34
- pathogenesis, 34
- pet autotransporter of, 336
- prototype strains and main virulence factors, strain heterogeneity, 31–33
- strains, 315
- Stx phage, 51
- toxins, 36
- transmission, 41
- treatment, 41
- urinary tract infection, 44
- vaccine development, 46
- virulence factors, 36–40
- virulence gene(s), 27, 51
- Enteroaggregative heat-stable toxin 1 (EAST-1), 37
- Enteroaggregative hemorrhagic *E. coli* (EAEHEC), 105–107
- Enterobacteriaceae*, 302, 310
- Enterocytes, 325, 330, 331
- Enterohemolysin (EhxA), 102
- Enterohemorrhagic *E. coli* (EHEC), 2, 98–117, 152, 226, 324, 325, 344
  - attaching and effacing (AE) lesion, 290
  - Bacteroides thetaiotaomicron*, 290
  - diagnosis, 357
  - EHEC SOS response, 291
  - infections, 357
  - in homeostasis and dysbiosis, 286
  - LEE and Stx expression, 291
  - produces StcE, 328
  - quorum-sensing (QS) signaling, 290
  - with spinach leaves, 334
  - virulence genes, 290
- Enteropathogenic *Escherichia coli* (EPEC), 2, 153–154, 324, 344
  - adherence factors, 5–7
  - adhesion to host cells, 70
  - adhesins and toxins, 3–4
  - in the Andes, 11–12
  - attaching and effacing lesion, 63
  - autoaggregation/biofilm formation, 64
  - bacteria, 345
  - Brazilian, 12–13
  - bundle-forming pilus, 65
  - in Central America, 13–14
  - CFA/I family, 19
  - CF-negative ETEC, 19
    - in Chile, 8–9
    - in Colombia, 10–11
    - classical and nonclassical antigens, 19
    - clinical considerations, 71–72
    - clonal lineages, 60
    - definition, 60
    - diagnosis, 69–71, 345, 357
    - and diarrheagenic *Escherichia coli*, 2
    - EAF plasmid, 64–65
    - early diagnostic procedures for, 345
    - epidemiological studies, 16
    - EspC, 67
    - fimbriae, 67–68
    - flagella, 68
    - global significance, 2–3
    - highlands of Bolivia, 9–10
    - immunogenicity and protection, 1
    - in Latin America, 8–15
    - incidence, 60–61
    - intimin and Tir, 66
    - invasion, epithelial cells, 64
    - LEE pathogenicity, 65–66
    - localized adherence to epithelial cells, 62–63
    - lymphostatin, 66–67
    - matched case-controls, 19
    - in Mexico, 14–15
    - nonclassical adhesins, 7–8
    - nonclassical toxins, mucinases and metalloproteases, 4–5
    - pathogenesis, 69
    - pediatric diarrheal diseases, 1
    - photomicrography and electron-micrograph, 63
    - plasticity, 20
    - reemergence, 62
    - serogroups, 344
    - toxins, 67
    - transmission and reservoirs, 62
    - type-3 secretion system of, 325
    - vaccines, 15–16
    - virulence factors, 19, 68–69
    - virulence genes in, 324
- Enterotoxigenic *Escherichia coli* (ETEC), 154–155, 253, 324, 344
  - ACE527 and ETVAX, 252–254
  - autotransporter proteins, 261
  - colonization factors, 257–258
  - EaeH adhesin, 260
  - EatA protease, 260
  - epitope-based antigens, 258
  - EtpA adhesin, 259
  - flagellin proteins, 261
  - hyperimmune bovine colostrum, 254
  - LT patch, 255

- Enterotoxigenic *Escherichia coli* (ETEC) (*cont.*)  
 mutant LT, 256  
 plant-based vaccines, 261  
 STa toxoids, 256–257  
 toxoid–CFA fusions, 258–259  
 YghJ metalloprotease, 260
- Enzyme immunoassay (EIA), 344
- Enzymes, 327
- EPEC adherence factor (EAF), 60, 64–65, 68, 69
- EPEC O127, 324
- EPEC-secreted protein, 65
- Epidemiology  
 aEPEC, China, 89  
 aEPEC, Latin America, 86  
 EAEC infection, 42  
 etiology of acute diarrhea, 48–49  
 in humans, 46
- Episomal DNA, 302
- Epithelia, intestinal, 328
- Epithelial intestinal cells, 330, 331
- Epithelial restitution, 328
- Epithelial to mesenchymal transition (EMT), 136
- Epithelium, 334
- ESBL *E. coli* infections, 307
- ESBL *E. coli* resistance, 306, 313
- Escherichia coli* (*E. coli*), 98, 206–212, 301, 311, 312  
 adhesins, mosaic of, 334–335  
 adhesins recognizing EM proteins, 332  
 animals and humans, 150  
 APEC, 160, 161  
 bacteria, 345  
 broiler chicken with, 307  
 colonies, 344  
 CS6 fibrillae of human, 329  
 DAEC, 152  
 diarrheagenic, 149  
 EAEC, 151, 152  
 eco-epidemiology, 149  
 EIEC, 152  
 endometrial pathogenic, 162  
 EPEC, 153, 154  
 ETEC, 154, 155  
 ExPEC cause diseases, 159  
 ExPEC control, 166  
 extra-intestinal, 149  
 genes encoding virulence factors, 150  
 genomes, 308  
 host interactions, 324–326, 335  
 InPEC control, 163–166  
 intestinal infections, in North and Central America, 311, 312  
 intestinal pathogenic, 150–159  
 MPEC, 159, 160  
 mucin glycan receptors, 328–329  
 neonatal meningitis, 162–163  
 NTEC, 163  
 sepsis-associated pathogenic, 162–163  
 STEC, 156–159  
 toxin genes, 349  
 transmission of resistant, 301  
 UPEC, 161  
 virulence genes in, 324
- Espinoza, R., 294
- ETEC autotransporter (EatA), 4, 5, 7–9
- ETEC-infected stool cultures, 345
- Etiologic agent, 306
- ETVAX vaccine, 252, 254
- Eukaryotic surface molecules, 325
- European multicenter prospective quarterly point-prevalence study of community-acquired diarrhea (EUCODI), 61
- Event-based surveillance, 111
- ExPEC control, 166
- ExPEC pathogens, 311
- ExPEC, antibiotic resistance of  
 in North and Central America, 309–311  
 in South America, 312–313
- Extended spectrum  $\beta$ -lactamases (ESBLs), 267, 304, 305  
*E. coli* strains, 312  
 infections, 307  
 genes encoding, 311  
 producers, 312  
 resistance, 313  
 resistant strain, 306
- External nucleic acid extraction, 352
- Extracellular matrix (EM), 325, 331, 332
- Extra-intestinal *E. coli* infections, 301, 305
- Extra-intestinal pathogenic *Escherichia coli* (ExPEC), 44, 159–163, 206–214, 235, 309  
 advances, 212–214  
 Latin America, 214–215
- Extra-intestinal pathogroups, 159
- Ezrin/radixin/moesin (ERM), 130
- F**
- Fas-associated DD protein (FADD), 229
- Fecal specimens, pathogens in, 347
- Fernández, D., 156
- F4 fimbriae of animal ETEC, 329
- F17G tip adhesin, 329
- Fibronectin, 331, 336
- Fibronectin-associated bacteria, 333
- Fibronectin-binding proteins, 336

- FilmArray GI Panel (BioFire Diagnostics), 351  
 FilmArray system, 351  
 Fimbriae, 207, 211, 212, 334  
 Fimbrial adhesins, 325, 329, 334, 335  
*fimH* genes, 331  
 FimH tip adhesin, 329, 330  
 Fingerprinting analysis, 354  
 Flagella (H antigens), 207  
 Flagellin, bacterial agonist, 333  
 Flagellum, 207, 212  
 Fluorescent microbeads, 352  
 Fluorescent-actin-staining (FAS) assay, 69  
 Fluorophore type (TFP) primer, 352  
 Fluoroquinolone resistance, 303, 304  
   among ST131 R30 clones, 308  
   clone, 308  
 Fluoroquinolones, 304, 305  
 Food microbial ecology, 180  
 Food products, *E. coli*, 178–179  
   AFC, 189  
   bacteriological analytical manual, 189  
   contaminated with STEC non-O157, 189  
   DEC (*see* Diarrheagenic *E. coli* (DEC))  
   *E. coli* O157:H7, 188–190, 194, 195  
   eating utensils, 195  
   emerging processing techniques, 186  
   epidemiological surveillance systems,  
     175–176  
   factors, 173  
   fecal contamination/unsanitary  
     processing, 188  
   food security, 174  
   foodborne diseases, 173, 175  
   “Healthy Butcher Shop”, 195  
   high-pressure homogenization and  
     processing, 184  
   hurdle technology, 186–187  
   HUS in patients, 195  
   ICMSF, 188  
   intense light pulses, 185  
   microbiological testing, 187  
   noncommercial RT-PCR tests, 189  
   organic acids, 186  
   outbreak studies, 176–178  
   ozone, 186  
   preventative approach, 174  
   pulsed electric field, 184  
   quality assurance systems, 174  
   quantitative risk assessment, 196–197  
   radiation, 185  
   sampling plans, 188  
   STEC serogroups, 194  
   STEC strains, 195  
   strategic control, 174  
   *stx* genes, 194  
   ultrasound, 185  
   ultraviolet light, 184–185  
 Food-borne disease, 111–116  
 Food-borne emerging enteropathogen, 27  
 Freitag, T., 166  
 Freitas Filho, E.G., 157
- G**
- Gastrointestinal epithelial cells, 326  
 Gastrointestinal tract, 326  
 Gel, biochemically complex, 326  
 Gene detection, 356  
 Genome sequencing, 352  
 Genotypes, multi-resistant clone, 307  
 Genotypic-based methods, 302  
 Gentamicin resistance, 310  
 Global Enteric Multicenter Study (GEMS), 2,  
   62, 361, 362  
 Globotriaosylceramide (Gb3), 99, 100, 102  
 Glycan–glycan interactions, 330  
 Glyco-based assays, 359  
 Glycoconjugates, 359  
 Glyco-engineering method, 359  
 Glyco-iELISAs, 359  
 Glycoproteins receptors, 333  
 Glycoproteins, immunoglobulin-related, 330  
 Glycoproteins, recombinant, 359  
 Glycosaminoglycans (GAGs), 329  
 Glycosidases, 327  
 Glycosylation, 326, 327  
 Gold standard method, 346  
 GoldenGate assay, 352  
 Good hygiene practices (GHP)  
   principle, 187  
 Good manufacturing practices (GMP)  
   principle, 187  
 Gram negative bacteria, 208, 214, 302,  
   303, 333  
   adhesins, 238  
   description, 231  
   secretion system, 239  
   T2SS, 222  
   T3SS, 223  
 Gram-positive bacteria, 333  
 Granulocyte-macrophage colony-stimulating  
   factor (GM-CSF), 42  
 GroEL protein, 336  
 Growth-related gene product (GRO)- $\alpha$ , 42  
 Guinea pig Sereny eye test, 345  
 Gut microbiome metabolism, 291, 293  
 Gut mucosal epithelium, 334  
 Gut mucus, 326–328

**H**

- H antigen, 206
- H11 flagellin, 336
- H30 genotype, 306
- Hazard Analysis Critical Control Point (HACCP) principle, 187
- Hazen, T.H., 86
- Healthy Butcher Shop, 195
- Healthy human intestinal microbiome, 284–285
- Heat-labile toxin, 345
- Hemolytic uremic syndrome (HUS), 44, 98–110, 112–115, 117, 176, 177, 195, 262, 335, 346
- Hemorrhagic coli type IV pilus (HCP), 334
- Hemorrhagic colitis (HC), 98, 99, 101, 104, 105, 156, 346
- HEp-2 assay, 69
- HEp-2 cell cultures, 345
- Heparin/heparan sulfate, 329
- Hernandes, R.T., 78
- Heterodimeric glycoproteins, 333
- High-resolution melting analysis (HRM), 349
- Homeostasis vs. dysbiosis
  - AIEC, 286
  - adhesion, 285–287
  - in the Americas, 293–295
  - diversity, 288–289
  - E. coli* Nissle, 286
  - in *E. coli* research, 284–289
  - EHEC, 286, 289–291
  - intracellular survival, 287–288
  - invasion, 287
  - mammalian gastrointestinal tract, 282–284
  - Nissle 1917 and homeostasis, 291–293
- Homo-tag assisted non-dimer system, 349
- Host cell glycans, 330
- Host cell receptors, 324, 334
- Host-specific factors, 324
- Human carcinoembryonic antigen cell
  - adhesion molecules (hCEACAMs), 130, 131, 136
- Human decay-accelerating factor (hDAF), 129–133, 135, 136
- Human ETEC infections, 17–18
- Human intestine, 326
- Human microbiome, 291
- Human pathogenic *E. coli*, 329
- Human  $\beta$ -defensin 2 (BD2), 292
- Hurdle technology, 186–187
- HUS patients, 359
- Hyaluronic acid, 329
- Hybrid hypervirulent EAEC strain, 29
- Hybridization, 352

**I**

- Ibis T5000 Universal Biosensor, 356
- Immune system, 334
- Immunity-related GTPase family M (IRGM), 288
- Immunochromatographic assays, 362
- Immunochromatographic test, 344, 363
- Immunofluorescence method, 357
- Immunoglobulin-related glycoproteins, 330
- Immunological tests, *E. coli*, 356–360
- In vitro organ culture (IVOC) models, 31
- Indicator-based surveillance, 111
- Indirect enzyme-linked immunosorbent assays (glyco-iELISAs), 357
- Infectious Diseases Society of America, 316
- Inflammatory bowel disease (IBD), 136, 285
- Inflammatory cascade reaction, 332
- Ingle, D.J., 83
- InPEC control, 163–166
- Integrated food chain surveillance, 111
- Integrin  $\alpha 5\beta 1$ , 333, 335
- Integrins, 325, 333
- Intense light pulses (IPL), 185
- Intensive care unit (ICU) facilities, 313
- Intermediate filament proteins, 336
- International public health authorities, 305
- Interventions
  - E. coli* O157:H7, 189
  - preslaughter, 197
  - surveillance data, 175
- Intestinal *E. coli*, 327
  - infections, 311
  - in North and Central America, 311–312
  - in South America, 313–315
- Intestinal epithelial cells (IECs), 285, 286
- Intestinal microbiota, 330
- Intestinal mucin, 328
- Intestinal mucus, 326
- Intimin recombinant antibody (scFv-intimin), 357
- Intracellular pathogens, 330
- Invasive strains, 345

**J**

- Jay-Russell, M.T., 153

**K**

- K antigen, 206
- K5 cell wall-associated polysaccharide (CPS), 292
- Kempf, F., 159
- Keratan sulfate, 329



- Keratins, 336  
 Knutton, S., 69  
 Kolenda, R., 157  
 Koohmaraie, M., 197
- L**  
 la Fuente De, M., 294  
 Labeling technique, 349  
 Labile enterotoxin B (LTB) subunit, 261  
 Labile Enterotoxin Output (LeoA), 5  
 $\beta$ -lactam antibacterial drugs, 304  
 $\beta$ -lactam resistance, 303–304  
 $\beta$ -lactamases  
   families of, 304  
   piggery reservoirs for, 305  
 Lactose negative, 344  
 Lactose-fermenting colonies, 361, 362  
 Laminin, 331  
 Latin America, 106, 111–117, 214–215  
   Argentina, 113  
   Bolivia, 115  
   Brazil, 114  
   Chile, 114  
   Costa Rica, 115  
   Paraguay, 115  
   Peru, 115  
   Uruguay, 114  
 Latin American Antimicrobial Resistance  
   Surveillance Network  
   (ReLAVRA), 312  
 Latin American countries, 361  
 LEE-encoded regulator, 65  
 LeJeune, J.T., 157  
 Lethal effect, 324  
 Ligand-receptor binding, 327  
 Ligands (adhesins), 325  
 Lineage-specific polymorphic assay, 109  
 Lipid, 330  
 Lipid-linked oligosaccharide, 359  
 Lipopolysaccharide (LPS), 101, 103, 114, 206,  
   208, 330  
 Lipopolysaccharide receptor CD14, 36  
 Liquid-array technology, 351  
 Liu, X., 161  
 Localized adherence (LA), 62, 345  
 Locus for enterocyte effacement (LEE), 65,  
   79, 101, 102, 104, 105, 110, 111,  
   156, 290  
 Locus-specific oligonucleotides (LSO), 352  
 Long polar fimbriae (Lpf), 286, 334  
 Loop-mediated isothermal amplification  
   (LAMP) assay, 348  
 LPS, bacterial agonist, 333  
 LPS-TLR4 signaling, 292  
 Luminex system, 352  
 LuminexTag gastrointestinal pathogen panel  
   (GPP), 351  
 Luna, E., 157  
 Luna-Guevara, M.L., 185  
 Lymphocyte inhibitory factor (LifA), 66  
 Lysine decarboxylase negative, 344
- M**  
 Major facilitator superfamily (MFS), 302  
 Majowicz, S.E., 176  
 Maluta, R.P., 154  
 Mammary pathogenic *E. coli* (MPEC), 159  
 Manning, S.D., 195  
 Mannose-rich uroplakin, 329  
 Manure on farms, animal, 305  
 Mass spectrometer, 354–356  
 Matrix-assisted laser desorption/ionization-  
   time of flight mass spectrometry  
   (MALDI-TOF-MS), 354  
   analysis, 354  
   biomarker, 355  
   data to identify microorganisms, 355  
   rapid availability of MLST, 355  
   studies using, 355  
 Mazumder, A., 153  
 Membrane integral proteins, 325  
 Membrane-associated cholesterol in  
   pathogen–host interaction, 330  
 Membrane-associated proteins, 335  
 Membrane-bound mucin, 326–328  
 Meningitis, 206, 207  
 Meningitis-associated temperature-dependent  
   fimbriae (MAT), 334  
 Metalloprotease, 328  
 Metallo- $\beta$ -lactamases, 304  
 Mexico, 214  
 Microarrays, 351  
 Microbial adhesins, 328  
 Microbiome dysbiosis, 290  
 Microbiota, natural, 326  
 Microorganisms, 327  
 Minimal inhibitory concentration (MICs), 15  
 Mitogen-activated protein kinases (MAP  
   kinases), 130  
 Molecular approach, 349  
 “Molecular bridge”, 336  
 Molecular microbiology laboratory, 348  
 Molecular pathogenesis, 353  
 Molecular risk assessment (MRA), 104, 105  
 Molecular serotyping methods, 349  
 Molecular techniques, Monobactams, 307, 353

- Monovalent EIEC, 345  
 MS fragmentation methods, 356  
 Mucinase, 328  
 Mucin-containing gels, 328  
 Mucins, 325–328  
   glycans, 327  
   glycoproteins, 328  
   glycosylated, 326  
   membrane-bound, 327, 328  
   oligosaccharides, 327  
   proteolytic cleavage of, 328  
   types of, 326  
 Mucolytic, 328  
 Mucosa, 326  
 Mucosal epithelial cells, 326  
 Mucus  
   degradation, 328  
   inner layer, 326  
   viscous nature of, 326  
 Multicolor combinatorial probe coding (MCPC), 349  
 Multidrug and toxic compound extrusion (MATE), 302  
 Multidrug-resistant *E. coli*, 310, 313  
 Multidrug-resistant *E. coli* sequence type 131 (ST131), 305  
 Multidrug-resistant organisms, 305  
 Multiepitope fusion antigen (MEFA), 258, 259  
 Multilocus sequence typing (MLST), 10, 11, 89, 106, 107, 116, 353, 355  
 Multiplex reactions, 361  
 Multiplex real-time PCR assay, 350  
 Multiplex systems, 348  
 Multiplexing reactions technology, 348  
 Multiplex-PCR system, 348  
 Multi-resistant clone, genotypes, 307
- N**
- N-acetyl neuraminic acid (Neu5Ac), 290  
 N-acetyl-glucosamine (GluNAc), 290  
 Nanometer-thin micropodial extensions (NMEs), 227  
 National Health Surveillance System, 360  
 National Reference Laboratory (NRL), 113–115  
 Natural microbiota, 326  
 Necrotogenic *E. coli* (NTEC), 163  
 Neonatal meningitis *E. coli* (NEMEC), 162–163, 206  
 Neter, E., 60  
 Neural Wiskott-Aldrich syndrome protein (N-WASP), 80, 82  
 Neutrophil extracellular traps (NETs), 135
- Next-generation sequencing (NGS), 352  
*Nle* genes, 104, 105  
 NleD-mediated cleavage, 229  
 NOD2 intracellular receptor, 288  
 Non-coding RNAs (ncRNAs), 231  
 Non-conjugative plasmids, 304  
 Non-ESBL *E. coli* strains, 312  
 Nonfimbrial adhesins, 329, 334, 335  
 Nonhuman primate model, 99  
 Non-lactose-fermenting colonies, 361, 362  
 Non-LEE (Nle)-encoded effector genes, 66, 82, 226  
 Nonmotile negative, 344  
 Non-polarized Caco-2 intestinal epithelial cells, 42  
 Nonspecific symptoms, 348  
 Nosocomial infection, 306  
 Novel receptors, 336  
 Nuclear factor-kB (NF-kB), 228  
 Nucleic acid amplification, 344, 348
- O**
- O antigen, 206  
 O serogroups, 349  
 O-antigen biosynthesis gene cluster analysis, 349  
 Ochoa, T.J., 78  
 O-glycosylated extracellular domain, 326  
 Oligomeric mucins, myriad of, 326  
 Oligomerized mucin macromolecules, 328  
 Omphalitis, 210  
 One-step multiplex PCR assay, 348  
 Open modular format, 350  
 O-polysaccharide-protein, 359  
 Osugui, L., 161  
 Otero, V., 89  
 Outer membrane porin C (OmpC), 333  
 Outer membrane porin F (OmpF), 333  
 Outer membrane vesicles (OMV), 287  
 Ozone, 186
- P**
- PacBio RS sequencer, 354  
 Pan American Health Organization (PAHO), 312  
 Paraguay, 115  
 Passenger associated transport repeat (PATR) motif, 233  
 Pathogen detection platform, 356  
 Pathogen-associated molecular patterns (PAMPs), 288, 332  
 Pathogenesis, 98, 101, 102, 117, 206–208, 211  
   AAF/II expression, 43–44

- bacterial, 325, 327, 330, 335
- EAEC, 27, 31
- enteric, 327, 328
- in fecal specimens, 347
- flagellar function, 327
- intracellular, 330
- Shigella* infections, 40
- T6SS, 40
- Pathogen–host interaction, membrane-associated cholesterol in, 330
- Pathogenic bacteria, 325
- Pathogenic *E. coli*, 324, 328
  - adhesins, 332
  - identification of, 353
  - strains, 325, 330
- Pathogenicity
  - aEPEC, 91
  - PAI-O122, 82
- Pathogenicity island (PAI), 79
- Patient management, 347
- PCR binary typing system (P-BIT), 104, 105
- Pediatric, antibiotic-resistant organisms in, 310
- Penicillins, 303, 307
- Periplasm, 359
- Persad, A.K., 157
- Pet autotransporter of EAEC, 336
- Peyer's Patches (PP), 286
- Phagocytosis, 333
- Phenotypic methods, 302
- Phosphatidylinositol 3-kinase (PI3K)
  - activity, 132
- pH-resistant bacteria, 324
- Phylogenetic analysis, 353, 354
- Phylogenomic analysis, 308
- Picco, N.Y., 155
- Piggery reservoirs for  $\beta$ -lactamases, 305
- Plasmid-encoded regulator (Per), 64, 68
- Plasmid-mediated quinolone resistance (PMQR) gene, 304, 315
- Polyethylene film, *E. coli*, 183
- Polymerase chain reaction (PCR)
  - assay, 349
  - based amplification, 348
  - method, 349
  - probe based tests, 349
  - techniques, 346
  - tests, 345
- Polymorphonuclear lymphocytes (PMNL)
  - infiltration, 133
- Polypeptide-transport-associated (POTRA)
  - motifs, 236
- Polysaccharide-containing structures, 335
- Polyvalent EIEC, 345
- Pooling method, 345
- Porcine intestinal glycosphingolipids, 329
- ppdD* gene, 334
- Predominant antimicrobial-resistant clone, 306
- Premier EHEC, 347
- Prioste, F.E.S., 160
- Probe-labeling strategy, 349
- Probiotics, 291
- Prodesse® ProGastro SSCS Assay (Gen-Probe Prodesse), 350
- ProGastro SSCS assay, 350
- Proline-rich glycoproteins, 326
- ProSpecT Shiga Toxin, 347
- Prostatitis, 206
- Protein involved in colonization (Pic)
  - mucinase, 328
- Protein secretion systems
  - AT classification, 234
  - autotransporter biogenesis, 233–234
  - autotransporter proteins, 232
  - bacterial processes, 221
  - cell survival, 229–230
  - classical and TPS ATs, 238
  - gram-negative envelop, IM and OM, 222
  - HlyA, 222
  - IgA1 proteases, 234
  - immune responses, 228–229
  - injectisome, 224
  - intimin, 238–239
  - invasins, 239
  - inverse ATs, 238–239
  - mammalian cells, 244
  - organelle, 239–241
  - prokaryotic and eukaryotic cells, 242–243
  - regulation of T6SS, 242
  - re-programming cytoskeleton, 227–228
  - Sec apparatus, 222
  - self-associating autotransporters, 235–236
  - SPATES, 235
  - subtilase-like ATs, 235
  - T2SS, 222
  - T3S
    - hierarchy and timing, 223
    - injectisomes and flagellum, 225
  - T3SS, 223–231
    - effectors, 226–230
    - regulators, 230–231
    - translocators, 225–226
  - T5SS, 231–239
  - T6SS, 239–244
  - TAA, 237, 238
  - TPS, 236
- Protein translocation
  - bacterial cells, 243
  - eukaryotic cells, 243

## Proteins

- E. coli* adhesins recognizing, 332
- in *E. coli* adherence, 335–336
- EM, 332
- family of, 332

Proteoglycans (PG), 325, 329, 330

Proteomic approach, 336

Pulsed electric field (PEF), 184

Pulsed field gel electrophoresis (PFGE), 89

PulseNet Latin America and the Caribbean (PNALC), 113, 116

Pyelonephritis, 206–208, 212–214

## Q

Quinolone resistance, 304, 315

Quorum sensing (QS), 182, 231, 290

## R

Rabbit antiserum, 345

Rabinovitz, B., 164

Real-time PCR, 348, 349

Receptors

- glycoproteins, 333
- novel, 336

Receptors, host-cell, 324

Recombinant B subunit of the cholera toxin (rCTB), 16

Recombinant exoprotein of *Pseudomonas aeruginosa* (rEPA), 265

Recombinant glycoproteins, 359

Recurrent UTIs (rUTIs), 206, 207, 212

Regional Technical Advisory Group, 312

Regulation

- DEC, 174
- European Commission, 188
- FDA, 186

ReLAVRA, 312

Reservoir

- aEPEC, 153
- ExPEC, 166
- rabbits and aEPEC, 154
- STEC, 151, 164
- transmissible pathogens, 158
- typical EAEC, human, 151

Resistance nodulation division (RND), 302

Rocha, S.P.D., 80

Ross, B.N., 51

Routine microbiology laboratories, 344

## S

S10-*spc*-alpha operon gene-encoded ribosomal protein mass spectrum (S10-GERMS) method, 355

*Salmonella enterica* serovars, 7

Samegima, D., 294

Sanger's sequencing method, 352

SARAMIS™ (BioMérieux), 355

Saviolli, J.Y., 160

Screening tests, 362

Secreted mucins, 326, 327

Self-associating autotransporters (SAAT), 234, 235

Self-ligands with signaling motifs, 333

SepA-hydrolyzed peptides, 39

Sepehri, S., 294

Sepsis-associated pathogenic *E. coli* (SePEC), 162–163

Septicemic *E. coli*, 235

Serine protease autotransporters of *Enterobacteriaceae* (SPATE), 5, 38, 133, 234, 235

Serine/threonine/proline (STP), 129

Serine-rich glycoproteins, 326

Serogroup-specific primer pairs, 349

Serological method, 355

Seropathotype, 104, 105

Serospecificity, 359

Serotype-level identification, 355

Serotyping-based diagnosis, 360

Severe-combined immunodeficient (SCID) mice, 43

Shiga toxin (Stx), 7, 29, 98–104, 106, 107, 110

Shiga toxin-producing *E. coli* (STEC), 2, 98–117, 156–159, 175, 176, 178–181, 184–187, 189, 190, 194–197, 324, 344, 346, 348, 362

anti-Stx treatments, 269–271

classical antibiotic treatment, 268

diagnosis, 272, 357

EHEC colonization, 269

epidemiological observation, 268

human infections by, 360

HUS development, 267

individuals, 268

ouabain, 271

QseC-mediated activation, 269

STEC O157 infections, 268

STEC/EHEC disease in in vitro model, 269

STEC/EHEC disease in in vivo model, 269

STEC/EHEC intestinal infections, 268

Stx absorption, 269

- Stx toxic effects, 271
    - telitromycin and solithromycin, 268
  - Shiga toxin-producing strains, 346
  - Shiga-toxin (Stx), 262, 357
  - Shigella*, 330
  - Shigella* enterotoxin 1 (ShET1), 37
  - Short-chain fatty acids (SCFA), 291
  - Shpigel, N.Y., 159
  - Siderophore receptor and porin protein (SRP), 164
  - Signaling lymphocytic activation molecule family (SLAMF), 325, 333
  - Signorini, M.L., 196
  - Silvera, E., 157
  - Single nucleotide polymorphism 13 (SNP13), 288
  - Single toxigenic culture analysis, 345
  - Slide agglutination test, 344
  - Small multidrug resistance (SMR), 302
  - Small, C.-L.N., 295
  - Smith, B.A., 196
  - Soft tissue infections, 306
  - Sorbitol nonfermenting colonies, 361
  - Sorbitol-fermenting colonies, 361
  - Species-level identification, 355
  - Spontaneous intestinal inflammation, 326
  - ST131 clones, CTX-M-15, 308
  - STa+ ETEC strains, 256
  - Staphylococcus aureus*, 336
  - Sterile organ-systems, 301
  - ST-positive strains, 345
  - Strains of Clade 8, 109
  - “Strain Solution” software, 355
  - Streptavidin–fluorophore conjugate, 352
  - Stx toxins, detection of, 357
  - Sulfatide glycosphingolipid, 329
  - Supplementary virulence genes (SVG), 47
  - Surface-exposed molecules, 325
  - Surface-exposed mucins, 326
  - Surveillance, 105, 106, 108, 111–117
  - Swollen-head syndrome, 210–212
- T**
- TaqMan Array Card (TAC) system, 350
  - TaqMan multiplex nucleic acid amplification assay, 350
  - Tarabla, H.D., 196
  - TccP/EspFU proline-rich repeat mimics, 227
  - Thomazini, C.M., 294
  - Threonine-rich glycoproteins, 326
  - Thrombotic microangiopathy (TMA), 100
  - Time of flight (TOF), 354
  - Tissue culture assays, 345
  - Tissue tropism, 329
  - TleA (Tsh-like ETEC), 7
  - TLR4 receptor, 208
  - TNFR1-associated death domain protein (TRADD), 229
  - Toll-like receptors (TLRs), 325, 332, 333
  - Topoisomerases type II DNA, 304
  - Toxins
    - holotoxin, 4
    - nonclassical, 4–5
    - potent enterotoxins, 4
    - rCTB, 16
  - Toxoid ST<sub>a</sub>P<sub>13F</sub>, 256
  - Translocated intimin receptor (Tir), 325
  - Transmembrane conductance of cystic fibrosis (CFTR), 4
  - Transmembrane glycoproteins, 326
  - Transmembrane immune receptors, 332
  - Transmission mechanisms, 306
  - Transmission of resistant *E. coli*, 301
  - Traveler’s diarrhea (TD), 29, 139
  - Trimeric autotransporters adhesins (TAAs), 237
  - Trimethoprim-sulfamethoxazole resistance, 310
  - Tumor necrosis factor (TNF- $\alpha$ ), 66, 100
  - Two chromosome-borne genes, 346
  - Two-tube multiplex real-time PCR assay, 350
  - Type 1 fimbriae, 329, 333, 334
  - Type 1 fimbrial adhesin *fimH30* allele, 307
  - Type III secreted proteins (TTSP), 164
  - Type III secretion system (T3SS), 79
  - Type III secretion system (TTSS), 101
  - Type-3 secretion system of EPEC, 325
  - Typical (tEPEC), 344
  - Typical EPEC strains, 60, 62, 64–66
- U**
- Uber, A.P., 151
  - Ulcerative colitis (UC), 285
  - Undecaprenol-phosphate (Und-P), 359
  - United States, 98, 101, 106–107, 109–112
  - Universal Biosensor assay, 356
  - Urinary tract infection (UTI), 206–208, 212, 214, 306, 313
  - Uropathogenic *Escherichia coli* (UPEC), 126, 130, 133, 135, 136, 161, 206–209, 211, 213, 214, 235, 329
  - Uropathogens, 206
  - Uruguay, 114
  - The U.S. Naval Medical Research Center (NMRC), 257

**V**

- Vaccines
  - diarrheal disease, 3
  - ETEC, 15, 16
- Variable heavy domain (VHH), 270, 271
- Vat-AIEC autotransporter, 286
- Vero cells, 99, 100, 108
- VHH-neutralizing agents (VNAs), 270, 271
- Viable non-culturable cells (VNCC), 182
- Viable-but-nonculturable (VBNC) cells, 348
- Vibrio cholerae*, 328
- Virulence factors
  - AE lesion, 79
  - DAEC
    - actin and tyrosine-phosphorylation of proteins, 134
    - EHEC, 134
    - EPEC, 134
    - flagella, 132–133
    - host cell responses, 134–135
    - Sat, 133–134
    - T3SS, 134
    - TLR1/TLR2, 134
  - diarrheal disease, 82
  - EAEC, 37, 45
  - EPEC, 78
  - plasmid-encoded, 33
  - unique immune-modulating bacterial, 39
- Virulence genes, 209
- Virulence marker antigen (VMA) ELISA, 345

- Virulence-associated genes, 309
- VTEC-Screen, 347

**W**

- Wells, J.E., 161
- Whole genome sequencing (WGS), 105–107, 109, 116, 117, 353
  - in public health services, 354
  - phylogenetic analysis by, 354
- Wiskott-Aldrich syndrome protein (WASP), 69
- Wong, C., 161

**X**

- xTAG Data Analysis Software for GPP, 352
- xTAG test for gastroenteritis agents (xTAG GPP), 352, 362

**Y**

- yghJ*, chromosomal gene, 328
- Yolk sac, 210

**Z**

- Zinc metalloprotease, 328
- Zoonosis, 301
- Zoonotic, 98, 102, 209